Funding

Bayer provided funding for the preparation of this article. 

Conflicts of Interest/Competing Interests

HW: honoraria; Astellas and Roche and travel expenses; Astellas and Ipsen. PH: consulting fees; Astellas, MSD, Pfizer, AstraZeneca, BMS and Ipsen. MPL: advisory role/speaker fees; Incyte, Amgen, Janssen Cilag B.V., Bayer, Servier, Roche, Pfizer Sanofi Aventis Netherlands BV and Astellas and has received research funding (institutional) from Sanofi, JnJ, Merck and Astellas. RDW: advisory role/speaker fees; Sanofi, Merck, Lilly, Roche, Bayer, Janssen Cilag B.V. and Clovis and research funding (institutional); Sanofi and Bayer. RHJM: has received research funding (institutional) from Bayer, Sanofi and Astellas.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Not applicable.

Code Availability

Not applicable.

Authors’ Contributions

Conceptualisation: SB, RdW, RM; methodology: SB, RM, SK, PdB; formal analysis: SB, EOdH; investigation: SB, NG; resources: PdB, SB; data curation: SB, NG, writing, original draft: SB; writing, review and editing: all authors.